Co-Authors
This is a "connection" page, showing publications co-authored by Wendy Stock and Caner Saygin.
Connection Strength
3.706
-
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 05 01; 5(3):164-179.
Score: 0.846
-
Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.
Score: 0.805
-
Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography-segmentation and a geriatric assessment. Leukemia. 2026 Aug 31.
Score: 0.248
-
Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2026 Aug 04; 25(8):1294-1304.
Score: 0.247
-
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 08 14; 15(1):138.
Score: 0.231
-
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
Score: 0.207
-
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022 12 01; 107(12):2783-2793.
Score: 0.192
-
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J. 2021 03 03; 11(3):48.
Score: 0.170
-
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019 12 23; 3(24):4228-4237.
Score: 0.156
-
Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2026 Jul 17; 32(14):3018-3030.
Score: 0.062
-
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
Score: 0.059
-
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. J Clin Oncol. 2025 11 10; 43(32):3526-3535.
Score: 0.058
-
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
Score: 0.057
-
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia. EJHaem. 2025 Feb; 6(1):e1076.
Score: 0.055
-
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2025 05 01; 110(5):1105-1114.
Score: 0.055
-
Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 10 10; 42(29):3478-3490.
Score: 0.054
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 06; 65(6):864-867.
Score: 0.052
-
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL. Leukemia. 2024 03; 38(3):491-501.
Score: 0.052
-
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 04; 204(4):1238-1242.
Score: 0.051
-
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemia. bioRxiv. 2023 Apr 25.
Score: 0.049